Clinical Trials Browser

Recruiting × INDUSTRY × Doxorubicin × Clear all

NCT04884035 2026-04-17

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Phase 1 Recruiting

Lymphoma, B-Cell

NCT06088290 2026-04-17

SaLuDo

Phase 3 Recruiting

Leiomyosarcoma, Neoplasms

NCT06966700 2026-04-17

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06717347 2026-04-16

MK-2140-010

Phase 3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05283720 2026-04-13

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-04-13

EPCORE™FL-2

Phase 3 Recruiting

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT06564038 2026-04-13

Soundtrack-E

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT07044336 2026-04-13

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Phase 3 Recruiting

Neoplasm Metastasis, Uterine Neoplasms, Endometrial Neoplasms

NCT07441460 2026-04-08

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Phase 3 Recruiting

Resectable HER2-positive Breast Cancer

NCT06890884 2026-04-02

MK-2140-011

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06340568 2026-03-31

Fern-EC-01

Phase 3 Recruiting

Endometrial Neoplasms

NCT06960577 2026-03-30

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT06797635 2026-03-13

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Phase 2 Recruiting

Breast Neoplasms

NCT06091254 2026-03-11

OLYMPIA-1

Phase 3 Recruiting

Lymphoma, Follicular

NCT06831370 2026-02-23

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Phase 4 Recruiting

Hodgkin Disease, Lymphoma

NCT06815575 2025-12-17

A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.

Phase 1 Recruiting

Other solid neoplasm

Solid Tumours

NCT06855069 2025-12-17

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT06911502 2025-12-05

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Phase 3 Recruiting

Lymphoma, Follicular

NCT06072131 2025-10-23

CRESCENDO

Phase 3 Recruiting

Lymphoma, T-Cell, Peripheral

NCT06947967 2025-09-15

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Phase 3 Recruiting

Lymphoma, T-Cell, Peripheral

NCT07124936 2025-08-15

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05279300 2025-08-11

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Phase 1 Recruiting

LymphoidOther solid neoplasm

Advanced Solid Tumor

NCT06277154 2025-07-24

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Phase 2 Recruiting

GynecologicSarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Endometrial Stromal, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

NCT05785754 2025-06-26

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT05615623 2025-04-30

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG

Phase 1/2 Recruiting

Brain Neoplasms

NCT06251180 2025-03-25

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

Lymphoma, B-Cell

NCT06584032 2025-01-07

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Phase 3 Recruiting

Endometrial Neoplasms

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Phase 1/2 Recruiting

DermatologicGastrointestinalGenitourinarySarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT06394492 2024-08-09

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT04650984 2024-04-08

FIBROSARC

Phase 3 Recruiting

Sarcoma